Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
The latest news, research, and perspectives in myeloproliferative neoplasms (MPNs). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Advertisement
Cecilia BrownMyeloproliferative Neoplasms | February 2, 2023
Hematocrit control was “suboptimal” in more than half of patients with high-risk polycythemia vera.
Read More
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | December 29, 2022
Ruben Mesa, MD, discusses his career in MPN treatment and research and notable abstracts at the 2022 ASH Annual Meeting.
Leah SherwoodMeeting News | December 20, 2022
Srdan Verstovsek, MD, discusses using machine learning to predict resistance to hydroxyurea therapy in polycythemia vera.
Cecilia BrownMyeloproliferative Neoplasms | December 20, 2022
Patients with MPN have a high risk of death from cardiovascular causes.
Cecilia BrownMyeloproliferative Neoplasms | December 20, 2022
Patients with MPN who are employed face a “high economic burden,” especially if they experience thrombotic events.
Cecilia BrownMyeloproliferative Neoplasms | December 20, 2022
Statin use may reduce the risk of developing a myeloproliferative neoplasm (MPN), according to a recent study.
Advertisement
Chadi Nabhan, MD, MBA, FACPVideo Insights | December 20, 2022
Chadi Nabhan, MD, MBA, FACP, interviews Srdan Verstovsek, MD, on highlights in MPN research at the 2022 ASH Annual Meeting.
Leah SherwoodVideo Insights | December 20, 2022
Srdan Verstovsek, MD, discusses the phase III VERIFY trial of rusfertide in patients with polycythemia vera.
Leah SherwoodMeeting News | December 12, 2022
Whole blood mutation allele frequency had only weak prognostic value in certain patients with polycythemia vera.
Keightley AmenMyeloproliferative Neoplasms | December 12, 2022
Several factors were independently associated with arterial thrombotic events in patients with myeloproliferative neoplasms.
Keightley AmenMeeting News | December 10, 2022
Symptom-related quality of life is linked with the type of cytoreductive treatment used for MPNs.
Kerri FitzgeraldMyeloproliferative Neoplasms | December 10, 2022
The combination of interferon and ruxolitinib may be a treatment option for newly diagnosed polycythemia vera.
Keightley AmenMeeting News | December 10, 2022
Long-term follow-up results of a phase II study of ruxolitinib in patients with MPNs were presented at the 2022 ASH Meeting.
Keightley AmenMyeloproliferative Neoplasms | December 9, 2022
New data support the use of ropeginterferon alfa-2b therapy in patients with low-risk or high-risk PV,
Keightley AmenMyeloproliferative Neoplasms | December 9, 2022
An analysis of patients with MF found that the combination of navitoclax and ruxolitinib reduced MF-associated splenomegaly.
Keightley AmenMyeloproliferative Neoplasms | December 8, 2022
IFNα2 treatment may help reduce the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms ...
Leah SherwoodMyeloproliferative Neoplasms | December 1, 2022
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
Leah SherwoodMyeloproliferative Neoplasms | November 29, 2022
The National Comprehensive Cancer Network publishes new MPN guidelines.
Leah SherwoodMyeloproliferative Neoplasms | November 29, 2022
Researchers published new classifications for MPNs and acute leukemias.
Cecilia BrownMyeloproliferative Neoplasms | November 16, 2022
Transfusion independence was associated with improved survival in studies of momelotinib in patients with myelofibrosis.
Advertisement
Advertisement
Editorial Board